EUVIMEDEUVIMED entdecken
Crossref

Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP

Huan Wen, Jing Lan, Kuo Dang, Yanli Wang, Daodong Pan iD, Xinchang Gao, Yali Dang

Journal of the Science of Food and Agriculture · 2026

DOI: 10.1002/jsfa.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, 2026. Verfasst von Huan Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Engineering, Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Ziziphus, Angiotensin-Converting Enzyme Inhibitors, Peptides. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Scientific and Technological Research Projects in Key Areas of Xinjiang Production and Construction Corps, Innovation Yongjiang 2035 Key R&D Programme - International Sci-tech Cooperation Projects, Quzhou City Science & Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND KALVAP is an angiotensin‐converting enzyme inhibitor derived from Ziziphus jujuba , but shows poor dipeptidyl peptidase (DPP)‐IV inhibitory activity. To remedy this shortcoming, KALVAP was modified according to the distinctive features of DPP‐IV inhibitory peptides, yielding nine novel peptides. The DPP‐IV inhibitory activity of the peptides was further verified in vitro and in vivo . RESULTS The in vitro DPP‐IV inhibitory activities of WALVAP and WPLVAP were respectively 6.25‐ and 3.52‐fold higher than that of KALVAP (360.39 ± 14.39 μmol L −1 ) after screening through molecular docking. Moreover, WALVAP (201.88 ± 8.27 μmol L −1 ) and WPLVAP (450.61 ± 16.83 μmol L −1 ) displayed superior DPP‐IV inhibitory activity to KALVAP (1372.57 ± 49.52 μmol L −1 ) in Caco‐2 cells. On the basis of in vitro and cellular experiments, oral glucose tolerance tests indicated that WALVAP and WPLVAP significantly improved glucose metabolism in C57BL/6 mice by promoting the secretion of insulin (11.13 ± 0.89% and 11.61 ± 0.44%), GLP‐1 (11.12 ± 0.89% and 11.61 ± 0.44%) and GIP (7.58 ± 0.78% and 7.66 ± 0.11%). Molecular dynamics simulations revealed that WALVAP and WPLVAP mainly inhibited DPP‐IV through Glu205, Trp629, Glu206, Arg125 and Arg429. CONCLUSION In summary, two new peptides, WALVAP and WPLVAP, were screened and exhibited excellent DPP‐IV inhibitory activity. The results implied that the optimization strategy is feasible and can provide a reference for drug design. Thus WALVAP and WPLVAP could serve as potential drug candidates for patients with hypertension and diabetes mellitus. © 2025 Society of Chemical Industry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsZiziphusAngiotensin-Converting Enzyme InhibitorsPeptidesPlant ExtractsAnimalsHumansMiceDipeptidyl Peptidase 4Molecular Docking SimulationMaleCaco-2 Cells

Stichwörter der Autor:innen

Caco‐2 cellDPP‐IV inhibitory activity optimizationOGTTZiziphus jujuba peptidepeptide modification

Substanzen

Dipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4Angiotensin-Converting Enzyme InhibitorsPeptidesPlant Extracts

Autor:innen und Institutionen

  • College of Food Science and Engineering, Ningbo University, Ningbo, China.
  • Institute of Drug Discovery Technology, Ningbo University, Ningbo, China.

ORCID-Profile: Daodong Pan

Förderung

  • Scientific and Technological Research Projects in Key Areas of Xinjiang Production and Construction Corps
  • Innovation Yongjiang 2035 Key R&D Programme - International Sci-tech Cooperation Projects
  • Quzhou City Science & Technology Plan Project
  • Science & Technology Department of Zhejiang Province

Zitieren

APA

Wen, H., Lan, J., Dang, K., Wang, Y., Pan, D., Gao, X., & Dang, Y. (2026). Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.70156

Vancouver

Wen H, Lan J, Dang K, Wang Y, Pan D, Gao X, et al. Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP. Journal of the Science of Food and Agriculture. 2026. doi:10.1002/jsfa.70156

BibTeX
@article{Wen2026,
  author = {Wen, Huan and Lan, Jing and Dang, Kuo and Wang, Yanli and Pan, Daodong and Gao, Xinchang and Dang, Yali},
  title = {Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP},
  journal = {Journal of the Science of Food and Agriculture},
  year = {2026},
  doi = {10.1002/jsfa.70156}
}
Kostenlos starten →